US FDA declines to approve Aquestive's oral drug for allergic reactions
02/02/2026 12:05
Feb 2 (Reuters) - The U.S. Food and Drug administration has declined to approve Aquestive Therapeutics' AQST.O oral drug for severe allergic reactions, the company said on Monday. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shilpi Majumdar) ((Padmanabhan.Ananthan@thomsonreuters.com;))
Recent news on Aquestive Therapeutics
See all newsBrief: Aquestive Therapeutics Inc - Enters Five-Year Term Loan Facility Of Up To $150 Million On May 12, 2026 - SEC Filing
Aquestive Therapeutics Q1 revenue jumps on higher license and royalty income
Brief: Aquestive Therapeutics Announces Completion Of Type A Meeting With FDA For Anaphylm™ (Dibutepinephrine) Sublingual Film
Aquestive misses Q4 revenue estimates, EBITDA loss widens
Brief: Aquestive Therapeutics, Inc. Q4 Net Income USD -31.86 Million